Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
GlaxoSmithKline has partnered with Exscientia to use artificial intelligence to develop small molecules against up to 10 drug targets. Exscientia seeks to use AI to design molecules with a desired balance of potency, selectivity, and pharmacokinetics. GSK will provide the firm with research funding and up to $42 million in milestone payments as molecules reach preclinical studies. In May, Exscientia joined with Sanofi to develop bispecific small molecules against metabolic diseases targets.
This article has been sent to the following recipient: